While antibody-drug conjugates have widespread treatment potential, the successful and safe manufacturing of these highly potent drugs requires a highly skilled team of experts and well-controlled manufacturing facilities. ADCs consist of three parts: an antibody specific to the target associated antigen, a payload designed to kill target cancer cells, and a chemical linker to attach the payload to the antibody.
We have leading capabilities and expertise in development across the ADC manufacturing parts: antibodies, payloads, linker and bioconjugation and sterile fill and finish. This integrated capability for the development and manufacture of ADC products can accelerate program timelines and reduce program complexity, resource requirements and risk.
We operate GMP production suites for gram-scale ADC payload production and multi-kilogram-scale production capacity at our site in Visp, Switzerland. End-to-end service programs can be readily arranged to meet your program needs. You can utilize our unique infrastructure for ADC payloads and overall ADC capabilities to avoid extra investment in expertise, assets and infrastructure required to work with these very highly potent applications.